Global Ventilator-associated Pneumonia (VAP) Market – Overview:
Ventilator-associated pneumonia is a type of pulmonary infection caused by patients on ventilation. Ventilator-associated pneumonia is mainly due to lung disease, neurological disorders, and trauma in severely ill people. The diagnosis of VAP requires aggressive monitoring associated with X-ray, bed, and microbiological examinations of respiratory secretions. Admission to growing ICs due to the increasing prevalence of respiratory diseases, an increasing number of IC beds, and the incidence of traumatic injuries provide a favorable context for market growth. Government following the objectives to enhance the healthcare capabilities with advanced equipment and modern infrastructure is predicted to uplift the growth of the global ventilator-associated pneumonia market Share
Intensive care patients need help for breathing, and a large number of people suffer from diseases such as heart disease that require continuous monitoring by the IC team. Ventilator-associated pneumonia is common in patients with IC. This is an important cause of morbidity and mortality in intensive care. This disease is the result of the presence of infected pathogenic secretions in the lungs. The long-term use of intensive care ventilators promotes the growth of this market. The increase in nosocomial infections is another factor that contributes to the growth of this market. Prevention of ventilator-associated pneumonia is important to protect the health of patients with life-threatening diseases.
Global Ventilator-associated Pneumonia (VAP) Market - Competitive Analysis:
June, 2016 - AstraZeneca had announced that the European Commission (EC) has granted marketing authorization for Zavicefta, which a combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalization. AstraZeneca is a global, innovation-driven biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas which are respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology and infection and neuroscience. Company operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. As per company reports, hospital-acquired pneumonia (HAP) denotes the development of lung infections after a patient has been hospitalized for a minimum of 48 hours.
Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/1377
However, after 48 hours, the infection develops during the use of incubation and mechanical ventilation, the condition is then called ventilator associated pneumonia (VAP). VAP is generally a severe illness, with patients requiring treatment in the intensive care unit (ICU). The approval includes intravenous use of Zavicefta for the treatment of patients suffering from intra-abdominal infections (cIAI); Complicated urinary tract infections (cUTI), including pyelonephritis; hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); and, the treatment of aerobic Gram-negative infections in adult patients who have limited treatment options. Zavicefta has been developed in response to the urgent need for new antibiotics to treat serious infections that are becoming increasingly resistant, such as multi-drug resistant P. aeruginosa, carbapenem-resistant Gram-negative pathogens, and ESBL-producing Enterobacteriaceae.
Jan, 2016 - Cepheid announced diagnostic collaboration with medimmune and combacte to facilitate clinical trials of new monoclonal antibodies to prevent serious infectious diseases. This Collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, and COMBACTE, a European public/private partnership set up to promote the development of new drugs in the anti-infectives field, to develop a series of rapid diagnostic tests to identify Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa) in respiratory secretions of mechanically ventilated patients. These tests will be used to help identify patients for MedImmune's MEDI4893 and MEDI3902 clinical programs, which are being conducted within the COMBACTE consortium to explore the use of biologics in preventing ventilator associated pneumonia (VAP) infections in intensive-care-unit (ICU) patients.
Philips Healthcare is one of the major market player in ventilation devices with its products named Respironic NM3, Respironic V680 and Respironic Trilogy 202.
Medtronic plc. is another major market player in this market with product like Puritan Bennet 980, Newport HT70 and Newport e360.
ResMed manufactures ventilation devices named Astral 150 and Astral 100.
Global Ventilator-associated pneumonia (VAP) Market - Regional Analysis:
The Americas is the leading regional market for ventilation-associated pneumonia (VAP), whose growth attributed to increased smoking prevalence, leading to lung disease, a large number of patients with chronic heart disease, and the demand for ventilators. The market is constantly growing in Europe due to the high demand, rising healthcare costs, and medical devices in hospitals.
The Asia Pacific region is expected to become the fastest-growing market due to increased environmental pollution, high occurrence of asthma, and chronic obstructive pulmonary disease, and a large patient population. In addition, awareness of the prevention of nosocomial infections, pneumonia, and the quality control measures taken by hospitals to combat nosocomial infections stimulate the growth of this market.
The aging population and the incidence of infectious diseases also contribute to the growth of this market in the Asia Pacific. On the other hand, the Middle East and the African region are expected to experience limited but steady market growth.
Browse Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/ventilator-associated-pneumonia-vap-market-1377
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]
Ventilator-Associated Pneumonia Market Synopsis:Ventilator-associated pneumonia is a respiratory disease caused to patients on ventilators.
According to Market Research Future (MRFR)’s study, the global ventilator-associated pneumonia market is projected to expand at a steady pace over the assessment period 2018 to 2023.The increasing cases of brain injuries owing to accidents and other hazards are also poised to favor the proliferation of the ventilator-associated pneumonia market over the next couple of years.
However, factors such as high ventilator charges, expensive diagnostic tests, risks associated with ventilators, etc.
are prognosticated to undermine pace of market growth in the years to come.Ventilator-Associated Pneumonia Market Segmentation:By diagnosis, the global ventilator-associated pneumonia market has been segmented into radiological examination, clinical examination, microbiological analysis, and others.
The microbiological analysis segment has been further sub-segmented into nonquantitative or semi-quantitative airway sampling, quantitative cultures of airway specimens, and blood and pleural fluid cultures.On the basis of mode of treatment, the ventilator-associated pneumonia market has been segmented into hospital care, homecare, and others.Based on end-user, the global ventilator-associated pneumonia market has been segmented into research centers, ambulatory care centers, hospitals & clinics, and Emergency Medical Services (EMS).
Market Research Future (MRFR) collected data on several factors including implications of Covid-19 Impact on Ventilator-Associated Pneumonia Market and demographic challenges, showed how it could move forward in the coming years.Ventilator-Associated Pneumonia Market Regional Analysis:The global ventilator-associated pneumonia market, on the basis of region, has been segmented into four key regions, namely Americas, Europe, Asia Pacific, and the Middle East and Africa (MEA).
